DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
Clinical trial NCT00353574 · TERMINATED
Trial details
- NCT number
- NCT00353574
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2006-09-01
- Primary completion
- 2010-02-01
- Enrollment
- 282
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.